Project Oncology®
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
MIRASOL Insights in PROC: A Biomarker-Driven Approach
Project Oncology®MIRASOL Insights in PROC: A Biomarker-Driven Approach
Investigator Perspectives on Treating Patients in a Ph2 NSCLC Trial
Project Oncology®Investigator Perspectives on Treating Patients in a Ph2 NSCLC Trial
Managing Capillary Leak Syndrome: Early Recognition and Intervention in BPDCN Care
Medical Industry FeatureManaging Capillary Leak Syndrome: Early Recognition and Intervention in BPDCN Care
Advancing Care in Pretreated HR+/HER2- mBC
Medical Industry FeatureAdvancing Care in Pretreated HR+/HER2- mBC
Supportive Care in Patients with Pretreated HR+/HER2- mBC
Medical Industry FeatureSupportive Care in Patients with Pretreated HR+/HER2- mBC
Helping Ensure Adequate Tissue Sampling Within the MDT
Medical Industry FeatureHelping Ensure Adequate Tissue Sampling Within the MDT
- advertisement
AI-Assisted Colonoscopy Improves Polyp Detection and Diagnostic Accuracy
Project Oncology®AI-Assisted Colonoscopy Improves Polyp Detection and Diagnostic Accuracy
ctDNA-Guided Immunotherapy Shows Survival Benefit in MIBC: IMvigor011 Results
Project Oncology®ctDNA-Guided Immunotherapy Shows Survival Benefit in MIBC: IMvigor011 Results
Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Project Oncology®Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Project Oncology®Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
Project Oncology®From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
Project Oncology®Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
- advertisement
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
CME/CEHER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
CME/CEAntibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
Reviewing the Latest Bladder Cancer Practice Guidelines
MinuteCE®Reviewing the Latest Bladder Cancer Practice Guidelines
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
MinuteCE®Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
- 01/02/2026
- 01/02/2026
- 01/02/2026
- 01/02/2026
- 01/01/2026
- 12/31/2025